- ►ahajournals.org RS Vasan - Circulation, 2006 - Am Heart Assoc Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality
in the United States. 1 Primary prevention and secondary prevention of CVD are
public health priorities. 2 Substantial data indicate that CVD is a life ... Cited by 189 - Related articles - All 14 versions
- ►ahajournals.org EL Schiffrin, ML Lipman, JFE Mann - Circulation, 2007 - Am Heart Assoc Accelerated cardiovascular disease is a frequent complication of renal disease.
Chronic kidney disease promotes hypertension and dyslipidemia, which in turn can
contribute to the progression of renal failure. Furthermore, diabetic ... Cited by 177 - Related articles - All 10 versions
- ►ahajournals.org R Schnabel, S Blankenberg, E Lubos, KJ … - Circulation research, 2005 - Am Heart Assoc As a competitive inhibitor of endothelial nitric oxide synthase, asymmetric
dimethylarginine (ADMA) has been related to atherosclerotic disease. Little is
known about the prognostic impact of baseline ADMA determination. In a ... Cited by 166 - Related articles - All 8 versions
- ►asnjournals.org P Ravani, G Tripepi, F Malberti, S Testa, F … - Journal of the American Society of Nephrology, 2005 - Am Soc Nephrol High plasma asymmetrical dimethylarginine (ADMA) signals endothelial dysfunction
and atherosclerosis in the general population and predicts mortality in ESRD.
The relationship among plasma levels of ADMA, renal function, and the risk ... Cited by 127 - Related articles - BL Direct - All 8 versions
- ►nih.gov [PDF] L Anderson - The Journal of Physiology, 2005 - Physiological Soc The key concept of proteomics (looking at many proteins at once) opens new
avenues in the search for clinically useful biomarkers of disease, treatment
response and ageing. As the number of proteins that can be detected in ... Cited by 114 - Related articles - BL Direct - All 16 versions
C Napoli, F de Nigris, S Williams-Ignarro, O … - Nitric Oxide, 2006 - Elsevier Nitric oxide (NO) is a molecule that has gained recognition as a crucial
modulator of vascular disease. NO has a number of intracellular effects that
lead to vasorelaxation, endothelial regeneration, inhibition of leukocyte ... Cited by 83 - Related articles - All 3 versions
- ►oxfordjournals.org JT Kielstein, SR Salpeter, SM Bode-Boeger, … - Nephrology Dialysis Transplantation, 2006 - ERA-EDTA Background. Dosing of most drugs must be adapted in renal insufficiency, making
accurate assessment of renal function essential in clinical medicine.
Furthermore, even modest impairment of renal function has been recognized ... Cited by 54 - Related articles - BL Direct - All 6 versions
- ►asnjournals.org T Nakagawa, W Sato, O Glushakova, M Heinig … - Journal of the American Society of Nephrology, 2007 - Am Soc Nephrol The pathogenesis of diabetic nephropathy remains poorly defined, and animal
models that represent the human disease have been lacking. It was demonstrated
recently that the severe endothelial dysfunction that accompanies a ... Cited by 48 - Related articles - BL Direct - All 6 versions
- ►asnjournals.org K Matsuguma, S Ueda, S Yamagishi, Y … - Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide
synthase. ADMA is generated by protein methyltransferase (PRMT) and is
metabolized mainly by dimethylarginine dimethylaminohydrolase (DDAH). ADMA ... Cited by 41 - Related articles - All 6 versions
- ►asnjournals.org HJ Zhao, S Wang, H Cheng, M Zhang, T … - Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol Functionally significant polymorphisms in endothelial nitric oxide synthase
(eNOS) and reduced vascular eNOS activity have been associated with increased
human diabetic nephropathy (DN), but the pathogenic role of eNOS deficiency ... Cited by 41 - Related articles - BL Direct - All 5 versions
